Logo image of EWTX

EDGEWISE THERAPEUTICS INC (EWTX) Stock Fundamental Analysis

NASDAQ:EWTX - Nasdaq - US28036F1057 - Common Stock

26.955  -0.44 (-1.59%)

Fundamental Rating

3

Taking everything into account, EWTX scores 3 out of 10 in our fundamental rating. EWTX was compared to 195 industry peers in the Pharmaceuticals industry. While EWTX has a great health rating, there are worries on its profitability. EWTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EWTX has reported negative net income.
EWTX had a negative operating cash flow in the past year.
EWTX had negative earnings in each of the past 5 years.
EWTX had a negative operating cash flow in each of the past 5 years.
EWTX Yearly Net Income VS EBIT VS OCF VS FCFEWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -24.31%, EWTX is in the better half of the industry, outperforming 60.22% of the companies in the same industry.
EWTX has a Return On Equity of -25.42%. This is in the better half of the industry: EWTX outperforms 68.82% of its industry peers.
Industry RankSector Rank
ROA -24.31%
ROE -25.42%
ROIC N/A
ROA(3y)-20.96%
ROA(5y)-23.12%
ROE(3y)-22.18%
ROE(5y)-24.3%
ROIC(3y)N/A
ROIC(5y)N/A
EWTX Yearly ROA, ROE, ROICEWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EWTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EWTX Yearly Profit, Operating, Gross MarginsEWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

EWTX has more shares outstanding than it did 1 year ago.
There is no outstanding debt for EWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EWTX Yearly Shares OutstandingEWTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
EWTX Yearly Total Debt VS Total AssetsEWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

EWTX has an Altman-Z score of 68.70. This indicates that EWTX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 68.70, EWTX belongs to the top of the industry, outperforming 97.85% of the companies in the same industry.
There is no outstanding debt for EWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 68.7
ROIC/WACCN/A
WACCN/A
EWTX Yearly LT Debt VS Equity VS FCFEWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

EWTX has a Current Ratio of 26.35. This indicates that EWTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 26.35, EWTX belongs to the top of the industry, outperforming 95.70% of the companies in the same industry.
A Quick Ratio of 26.35 indicates that EWTX has no problem at all paying its short term obligations.
EWTX has a Quick ratio of 26.35. This is amongst the best in the industry. EWTX outperforms 95.70% of its industry peers.
Industry RankSector Rank
Current Ratio 26.35
Quick Ratio 26.35
EWTX Yearly Current Assets VS Current LiabilitesEWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for EWTX have decreased by -5.63% in the last year.
EPS 1Y (TTM)-5.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

EWTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.55% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.49%
EPS Next 2Y-8.65%
EPS Next 3Y-10.58%
EPS Next 5Y10.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EWTX Yearly Revenue VS EstimatesEWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
EWTX Yearly EPS VS EstimatesEWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EWTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EWTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EWTX Price Earnings VS Forward Price EarningsEWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EWTX Per share dataEWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

EWTX's earnings are expected to decrease with -10.58% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.65%
EPS Next 3Y-10.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EWTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EDGEWISE THERAPEUTICS INC

NASDAQ:EWTX (1/22/2025, 10:33:58 AM)

26.955

-0.44 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-20 2025-02-20/amc
Inst Owners87.03%
Inst Owner Change-0.03%
Ins Owners0.49%
Ins Owner Change0.49%
Market Cap2.55B
Analysts84.62
Price Target50.42 (87.05%)
Short Float %8.3%
Short Ratio7.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.08%
Min EPS beat(2)3.18%
Max EPS beat(2)4.98%
EPS beat(4)3
Avg EPS beat(4)4.86%
Min EPS beat(4)-6.17%
Max EPS beat(4)17.47%
EPS beat(8)6
Avg EPS beat(8)5.71%
EPS beat(12)8
Avg EPS beat(12)3.87%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.45%
PT rev (3m)18.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.36%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.22
P/tB 5.22
EV/EBITDA N/A
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0
BVpS5.16
TBVpS5.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.31%
ROE -25.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.96%
ROA(5y)-23.12%
ROE(3y)-22.18%
ROE(5y)-24.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.97%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.35
Quick Ratio 26.35
Altman-Z 68.7
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)706.19%
Cap/Depr(5y)474.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.2%
EPS Next Y3.49%
EPS Next 2Y-8.65%
EPS Next 3Y-10.58%
EPS Next 5Y10.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.09%
EBIT Next 3Y-26.06%
EBIT Next 5Y14.96%
FCF growth 1Y-109.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-116.76%
OCF growth 3YN/A
OCF growth 5YN/A